Jim Simons’s IN8bio INAB Stock Holding History

Jim Simons’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1K	Buy	+12,100	New	+$18.2K	﹤0.01%	3101
2024 Q2	–	Sell	-3,972	Closed	-$141K	–	3719
2024 Q1	$141K	Buy	3,972 +3,319	+508%	+$125K	﹤0.01%	3299
2023 Q4	$27K	Buy	+653	New	+$20.9K	﹤0.01%	3546
2023 Q3	–	Sell	-723	Closed	-$33K	–	3873
2023 Q2	$33K	Buy	+723	New	+$45.2K	﹤0.01%	3686

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jim Simons's INAB Position: Q2 2026 in Review

Jim Simons opened a new position in IN8bio (INAB) in Q2 2026: 12,100 shares worth $17.1K. The stake represents ﹤0.01% of the portfolio and ranks #3101 among its holdings. This is a return to the name: Jim Simons previously reported a position in INAB as recently as Q1 2024.

Jim Simons first reported a position in INAB in Q2 2023 and has held it in 4 quarters since. The position peaked at $141K in Q1 2024. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

Jim Simons held 12,100 shares of IN8bio worth $17.1K as of Q2 2026.
IN8bio was a new Jim Simons position in Q2 2026.
IN8bio made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #3101 holding.
Jim Simons first reported a position in IN8bio in Q2 2023 and has held it in 4 quarters since.
Jim Simons's IN8bio position peaked at $141K in Q1 2024.
21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.